North American monoclonal antibodies market is estimated to grow at a CAGR of 6.8% during the forecast period. Some pivotal factors encouraging market growth include a significant rise in cancer incidences and rising new FDA launches for monoclonal antibody drugs. Additionally, launches of monoclonal antibody biosimilars treatment are providing an opportunity for market growth. For instance, in January 2020, Pfizer launched three new biosimilars named rituximab-pvvr (Ruxience), trastuzumab-qyyp (Trazimera), and bevacizumab-bvzr (Zirabev) in the US. This is expected that the specialty drugs will be launched at the lowest wholesale acquisition cost (WAC) among trastuzumab, bevacizumab, or rituximab products currently on the market. These drugs will become available at a discounted price than their equivalents brand name. 

This launch can support significant savings for the healthcare system in the US while enhancing access to vital therapies. Pfizer is looking forward to work with providers and payers to offer these essential medications to patients who are suffering from certain cancers and autoimmune conditions. These new biosimilars will enable healthcare providers to deliver additional treatment options for patients across 9 cancer forms, including metastatic colorectal cancer, recurrent, or metastatic cervical cancer, breast cancer, metastatic renal cell carcinoma, and others.

North American monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. In 2019, cancer held the largest share in the market owing to the increasing preference for monoclonal antibody drugs for cancer treatment in the region. It acts as a targeted and immunotherapy to find and destroy cancer cells. Additionally, an increasing number of clinical trials for cancer monoclonal antibodies is further anticipated to drive the market growth.

Some key players in the market include Amgen Inc., Eli Lilly & Co., Pfizer Inc., Merck & Co., Inc., and F. Hoffman La-Roche AG. They are using some crucial strategies to increase their market share. For instance, in December 2019, Mylan N.V. and Biocon Ltd. declared the introduction of Ogivri (trastuzumab-dkst) in the US, which is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer.

Research Methodology

The market study of the North American monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. North American Monoclonal Antibodies Market Research and Analysis by Source
2. North American Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the North American monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the North American monoclonal antibodies market.
• Insights about market determinants which are stimulating the North American monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.